[89Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors
In this work, [<sup>89</sup>Zr]Zr-DFO-TOC was synthesized with radiochemical yields ≥ 95% and was found to remain stable in vitro at extended time points. In vitro cell studies demonstrated a statistically significant difference between receptor binding and blocking experiments. The development of this work shows potential to positively impact patient care through the predictive dosimetry calculations for the FDA-approved therapeutic agent [<sup>177</sup>Lu]Lu-DOTA-TATE, while allowing for imaging at extended timepoints and should be studied further.
Authors
- Nikki A. Thiele (ORCID: https://orcid.org/0000-0003-3301-0849)
- Kate Perry (ORCID: https://orcid.org/0000-0002-2489-4729)
- E. J. Williams (ORCID: https://orcid.org/0000-0001-8218-2060)
- Ivis F. Chaple (ORCID: https://orcid.org/0000-0003-3951-3594)
- Alexis M. Sanwick
- Katherine N. Haugh
Institutions
- Oak Ridge National Laboratory (US)
- Knoxville College (US)
- University of Tennessee at Knoxville (US)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s41181-024-00320-9
- Citations
- 4
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.55